NZymeCeuticals, Inc., (d/b/a NZyme) a company established in 2002, will begin to market "Platinum Nattokinase" (PN20K) Sept. 2008. Dr. Ralph E. Holsworth, President of NZymeCeuticals, Inc., announced Friday the company will begin to market the new line of bulk powder enzyme ingredient, nattokinase as "PN20K" to North and South America.
Durango, CO (PRWEB) September 8, 2008 -- "PN20K" is a pro-fibrinolytic enzyme that is extracted from a particular type of fermented soybean (natto) and renown in the dietary supplement industry and medical field for its "blood clot busting" abilities. "The new line has been in development for the past two years in Japan and establishes the 'platinum' standard for nattokinase." "PN20K is patent protected and manufactured by an ISO 9000 certified Japanese manufacturer," says Dr. Holsworth. A number of Japanese researchers and Dr. Holsworth collaborated on specific characteristics of nattokinase, enhancing the specificity of nattokinase's ability to breakup "cross-linked" fibrin and increasing its stability in clinical settings. In addition, PN20K significantly improves the way blood flows and enhances human microcirculation, promising novel therapeutic modalities for hypertension, coronary artery disease, diabetes, cerebrovascular accidents and deep vein thrombosis.
Dr. Holsworth first introduced nattokinase to the United States in 2002. Since then, the ingredient has gained much attention largely due to its naturally occurring "blood clot busting" ability. During this time, Dr. Holsworth and Dr. Sumi (the discoverer of nattokinase) have met several times in Japan and the USA to discuss the therapeutic properties of the enzyme and its future medical use. Over the years, Drs. Holsworth and Sumi continue to collaborate on the studies and findings of nattokinase. Initial research indicates PN20K has the potential to significantly impact cardiovascular diseases because of its ability to change chemical and physical characteristics of blood, providing a "one-two punch." "We simply don't see these positive effects with typical pharmaceutical drugs," says Dr. Holsworth.
In Japan, the enzyme has an annual 15 billion yen market. Since its introduction to the U.S. market, bulk sales for the enzyme have experienced increased growth and demand. With different manufacturers of nattokinase from all over the world, the activity, stability and purity of the product varies significantly. NZymeCeuticals' bulk ingredients undergo third-party testing for quality assurance and quality control as well as to preserving the integrity of the new ingredient. Clinical research using PN20K as the therapeutic agent is well underway.
Read the full story at http://www.prweb.com/releases/nattokinase/holsworth/prweb1294934.htm
Copyright©2008 Vocus, Inc.
All rights reserved